Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male~* aged 50 years or older~* diagnostic claim for BPH~* prescription claim for an AB and a 5ARI in the observation period (5ARI must occur within a 6-month window after the AB).~* continuously eligible for 6 months prior to and 12 months after index prescription date~Exclusion Criteria:~* prostate or bladder cancer during the study period~* any prostate-related surgical procedure within 5 months of the index prescription date~* prescription claim for finasteride 1 mg for male pattern baldness during the study period~* 5ARI therapy prior to initiation of AB therapy

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early initiation of 5ARI therapy (Type: None): Patients starting 5ARI therapy within 30 days of initiating AB therapy
- Delayed initiation of 5ARI therapy (Type: None): Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).